SWG Educational Activities
European LeukemiaNet Symposium
Venice, 21-22 March 2018
- Chronic myeloid leukemia (CML), WP4 - The path to cure - M. Baccarani, S. Saußele
- Saußele: EURO-SKI (Stop Kinase Inhibitors) – What next?
- Mustjoki: Does the immune system contribute to treatment free remission?
- Baccarani : Discussing the ELN recommendations
- Soverini: Updating the ELN recommendations for mutational analysis
- Lauseker: The definition of progression in the tyrosine kinase inhibitor (TKI) era
- Hochhaus: New TKIs, ABL001 (Asciminib)
- Turkina: New TKIs, PF-116
- Hehlmann: Determinants of survival and center effects in CML
- Keynote lectures - R. Hehlmann, L. Chieco-Bianchi
- Ossenkoppele: Minimal residual disease (MRD) in acute myeloid leukemia (AML): can it already serve as a surrogate for survival?
- Barosi: The new ELN management recommendations for myeloproliferative neoplasms (MPN)
- Rössig: CAR-T-cells in hematologic neoplasias
- Baccarani: 50 years of chronic myeloid leukemia (CML) research: where do we stand today?
Meeting of the European Investigators on CML
Turin, 18-19 May 2018
Annually since 1992 EI-CML scientists gather together to discuss the most difficult and unresolved issues in CML research.
CML is an orphan disease, the incidence of which in population is less than 2 cases per 100,000 people. In this regard it is impossible to conduct research without collaboration, for example, merging of databases. In addition, all current research projects require high-tech research methods and are frequently expensive. Pooling of efforts of several countries is often needed for meaningful results.
Usually during EI-CML meetings each CML expert makes a short presentation on results of ongoing research and make suggestions for future work. Along with this merging efforts and creation of international cooperation are discussed. The EI-CML meeting format allows scientists to find each other and make plans for future joint work.
The main objectives of this meeting are: to share the vision of different European researchers and cooperative study groups on CML therapy, based on the review the most recently available clinical and biological data; to form a cooperative network able to explore potential integration of projects of the different European national research groups in CML; to promote new clinical trials and treatment strategies, aiming to improve the standard healthcare treatment and the quality of life of CML patients; to standardize the molecular diagnosis and follow-up of the CML patients; to explore the clinical relevance of advanced genomic technologies, like NGS and digital PCR, to analyze biological prognostic factors and MRD, the presence and/or the onset of resistance to therapy and the risk of progressive disease and the perspective of TFR (treatment free remission) in the present and future context of the CML therapy.
ELN Breakfast meeting at ASH
San Diego, 2 December 2018
Chairs: G. Saglio, Turin; A. Hochhaus, Jena
- EUTOS 2016 achievements, projects of EUTOS 2018
- Hochhaus: Introduction into the project
- Hochhaus: Molecular monitoring
- New technologies:
- Soverini: NGS
- Franke: ddPCR
- Machova: genomic PCR
- Burchert: Immune mechanisms
- Saussele: Treatment free remission projects